Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7302
    +0.0005 (+0.06%)
     

  • CRUDE OIL

    82.80
    -0.01 (-0.01%)
     

  • Bitcoin CAD

    88,238.82
    -3,086.99 (-3.38%)
     

  • CMC Crypto 200

    1,389.38
    -34.72 (-2.44%)
     

  • GOLD FUTURES

    2,321.10
    -17.30 (-0.74%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,458.25
    -206.25 (-1.17%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,818.11
    -641.97 (-1.67%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Teva to Present New Data for Fremanezumab

Sarah Collins
Updated
Teva to Present New Data for Fremanezumab

Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.

Continue reading